Phenotypic Characterization of Circulating CD4⁺ T Cells in ANCA-Associated Vasculitis

Table 1

Descriptive statistics of GPA and MPA (numbers or median with lower and upper quartiles) at time of blood sampling.

	GPA	MPA	value
Age in years	66.8 (50.9, 76.5)	75.7 (68.8, 82.4)
Sex (numbers)
Female	18	11
Male	20	11
Age at diagnosis in years	57.5 (35.9;67.3)	64.2 (73.2;76.2)
Follow-up time in months	81.9 (28.2;157.4)	16.7 (1.2;74.8)
ANCA specificity (numbers)
PR3	30	5
MPO	7	17
Disease activity (numbers)
Active disease	8	10
Remission	30	12
Time since onset of the last flare in months	34.4 (11.4;63.2)	8.9 (0.9;34.3)
Disease phenotype (numbers)
Localized disease	7	6
Systemic disease	31	16
Organ involvement (numbers)
Ear-nose-throat	30	1
Pulmonal	23	9
Renal	28	21
Central nervous system	4	1
Peripheral nervous system	4	5
Gastrointestinal	2	1
Cardiovascular	1	3
BVAS (Birmingham Vasculitis Activity Score) (numbers)
0	30	12
1–5	3	1
6–10	4	4
>10	1	5
Vasculitis Damage Index	2 (1, 4)	2 (0, 3)
CRP (mg/L)	3.4 (1.4, 6.1)	2.4 (1.4, 9.5)
Haemoglobin (g/L)	129.0 (122.5, 138.0)	124.0 (111.0, 133.5)
Platelets (10^9/L)	263.0 (204.3, 313.3)	230.0 (183.5, 287.5)
White blood count (10^9/L)	6.6 (5.2, 8.6)	7.3 (5.4, 8.4)
Creatinine (micromoles/L)	101.0 (72.5, 141.0)	158.0 (106.0, 199.3)
eGFR (mL/min/1.73 m^2)	64 (45, 86)	33 (21, 48)
Prednisolone (mg/day)
0	11	7
2.5–5	16	5
>5–10	10	2
>10–20	1	4
>20	0	4
Azathioprine	12	8
Median dose (mg/day)	125 (range: 50, 200)	75 (range: 50, 100)
Mycophenolate mofetil	5	0
Median dose (mg/day)	2000 (range: 250, 2500)	NA
Methotrexate	5	0
Median dose (mg/week)	25 (range: 15, 25)	NA
Cyclophosphamide po	0	0
Cyclophosphamide iv (within 6 months)	4	7
Median time since last infusion (days)	83.5 (31.8, 103.0)	18 (12.3, 135.8)
Rituximab (ever)	14	3
Median time since last infusion (days)	367.0 (139.5, 902.5)	316.0 (91.0, 973.0)

GPA = granulomatosis with polyangitis; MPA = microscopic polyangitis. ¹Mann-Whitney test, ²Fisher’s exact test, and ³chi-square test.